Presbyopia Clinical Trial Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

(Albany, US), On October 14, 2026 – DelveInsight’s “Presbyopia Pipeline Insight 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Presbyopia pipeline landscape. It covers the Presbyopia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Presbyopia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Presbyopia Pipeline @ https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight

Key Takeaways from the Presbyopia Pipeline Report

• October 17, 2026 – Viatris Inc. is awaiting an FDA decision on its supplemental application for phentolamine ophthalmic solution 0.75% (MR-141) for presbyopia. The FDA target action date is October 17, 2026
• October 13, 2026 – Azalea Vision BV conducted Azalea Vision is sponsoring a proof-of-concept study of its novel optical-aperture scleral contact lens for people with presbyopia and keratoconus. The study is designed to evaluate visual quality and is estimated to have started in October 2026.
• October 05, 2026 – Johnson & Johnson announced that its TECNIS PureSee and TECNIS Odyssey intraocular lenses had surpassed one million implants worldwide. These lenses offer advanced vision-correction options relevant to patients undergoing cataract surgery who also seek improved vision at different distances.
• DelveInsight’s Presbyopia Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Presbyopia treatment.
• The leading Presbyopia Companies such as Viatris, Glaukos Corporation, Tenpoint Therapeutics, Vyluma, and others.
• Promising Presbyopia Pipeline Therapies such as Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, Pilocarpine HCl, UNR844-Cl, CSF-1, AGN-190584, Pilocarpine Ophthalmic, Aceclidine, Brimonidine and others.

Get insights into clinical trials, emerging therapies, and leading companies with Presbyopia @ Presbyopia Treatment Drugs

The Presbyopia Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Presbyopia Pipeline Report also highlights the unmet needs with respect to Presbyopia.

Presbyopia Overview

Presbyopia is an age-related loss of lens accommodation that results in an inability to focus at near distances. It is the most common physiological change occurring in the adult eye and is thought to cause universal near vision. People who become presbyopia may complain of headaches and eye strain, and hold objects progressively further away from their eyes in order to be able to focus on them. The most common remedy is the prescription of a pair of reading spectacles. The prevalence of presbyopia in low- and middle-income countries is not well known, as most studies of refractive error in these countries have been limited to distance vision. There are various explanations about the pathophysiology of presbyopia. Among all the concepts, increased stiffness of the crystalline lens is the most popular and widely accepted. Presbyopia is a physiological condition wherein there is a progressive functional decline in the accommodative capacity of the crystalline lens. Clinically, it manifests as progressive difficulty in reading at the usual reading distance. Patients around 40 years of age present with complaints of difficulty in reading finger prints at usual reading distance.

Presbyopia Emerging Drugs Profile

• Phentolamine: Opus Genetics

Nyxol is a preservative-free ophthalmic solution that contains 0.75% phentolamine (1% phentolamine mesylate), a nonselective alpha-adrenergic antagonist which inhibits the contraction of the smooth muscle of the iris. Nyxol is being developed under the 505(b) (2) pathway. Ocuphire Pharma is developing it as a single drop as well as an adjunct therapy for the treatment of presbyopia. It has completed a Phase II trial to assess the safety and efficacy of Nyxol with low-dose pilocarpine eye drops in subjects. In various Phase II trials, Nyxol alone has reduced pupil diameter, improving visual acuity by one eye-chart line for over 24 hours after an evening eye drop. Currently, the drug is in the Preregistration stage for the treatment of Presbyopia.

• TPT-161: Tenpoint Therapeutics

TPT-161 is an investigational topical ophthalmic therapy being developed by Tenpoint Therapeutics for the treatment of presbyopia, an age-related loss of near vision. The product is designed to improve near visual acuity through a pharmacologic approach, potentially reducing dependence on reading glasses. TPT-161 combines pupil-modulating mechanisms to enhance depth of focus while maintaining distance vision and is being evaluated in clinical studies for its efficacy, safety, and duration of effect in adults with presbyopia. Currently, the drug is in the Preclinical stage for the treatment of Presbyopia.

The Presbyopia Pipeline Report Provides Insights into-

• The report provides detailed insights about companies that are developing therapies for the treatment of Presbyopia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Presbyopia Treatment.
• Presbyopia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Presbyopia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Presbyopia market

Explore groundbreaking therapies and clinical trials in the Presbyopia Pipeline @ New Presbyopia Drugs

Presbyopia Companies

Viatris, Glaukos Corporation, Tenpoint Therapeutics, Vyluma and others.

Presbyopia Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Presbyopia Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Learn about new Presbyopia Pipeline Drugs Developments @ Presbyopia Market Drivers and Barriers

Scope of the Presbyopia Pipeline Report

• Coverage- Global
• Presbyopia Companies- Viatris, Glaukos Corporation, Tenpoint Therapeutics, Vyluma and others.
• Presbyopia Pipeline Therapies- Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, Pilocarpine HCl, UNR844-Cl, CSF-1, AGN-190584, Pilocarpine Ophthalmic, Aceclidine, Brimonidine and others.
• Presbyopia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Presbyopia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth Presbyopia Pipeline report today! @ Presbyopia Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Presbyopia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Presbyopia – DelveInsight’s Analytical Perspective
7. Late Stage Products (Registration)
8. LNZ100: Lenz Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. GLK-302: Glaukos Corporation
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Preclinical Stage Products
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Presbyopia Collaborations Assessment- Licensing / Partnering / Funding
20. Presbyopia Unmet Needs
21. Presbyopia Market Drivers and Barriers
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/presbyopia-pipeline-insight